Stock Comparison

PFE vs TERN

Pfizer Inc vs Terns Pharmaceuticals Inc

Who's the better investment? Let's break it down.

The Verdict

PFE takes this one.

It's not even close. PFE outscores TERN by 3.9 points. That's a significant gap in our deep value framework.

Winner

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

TERN

Terns Pharmaceuticals Inc

0.1

out of 10

Distressed

Want to compare any two stocks?

Valuation

PFE

Metric

TERN

$146.4B

Market Cap

$6.1B

19.5

P/E Ratio

Lower may indicate better value

-51.4

8.1

Forward P/E

N/A

1.5

Price/Book

N/A

7.1

EV/EBITDA

N/A

Profitability & Growth

PFE

Metric

TERN

11.8%

Profit Margin

N/A

74.8%

Gross Margin

N/A

15.4%

Operating Margin

N/A

8.4%

Return on Equity

-20.0%

3.6%

Return on Assets

-19.4%

1.4%

Revenue Growth

-100.0%

$1.31

EPS

$-1.03

Financial Health

PFE

Metric

TERN

0.7

Debt-to-Equity

Lower = less leverage

0.1

1.2

Current Ratio

Above 1.0 is healthy

62.4

0.3

Beta

Lower = less volatile

-0.4

6.8%

Dividend Yield

None

Risk Comparison

PFE

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Low

Regulatory

Medium

What Could Go Wrong

The biggest risk for Pfizer is the ongoing and accelerated erosion of revenue from key patent expirations and declining COVID-related product sales (Paxlovid/Comirnaty). If the pipeline of new product...

Red Flags

🚩Adjusted EPS declined -18% YoY in Q1 2026 despite revenue beat, indicating continued margin pressure...
🚩High reliance on successful pipeline execution to offset significant revenue declines from mature pr...
🚩Market Cap ($146.42B) requires an unrealistic 10x growth to over $1.4 trillion in 3-5 years, a scale...

TERN

Overall

Not Applicable

Financial

Not Applicable

Market

Not Applicable

Competitive

Not Applicable

Execution

Not Applicable

Regulatory

Not Applicable

What Could Go Wrong

For former shareholders, the only remaining 'risk' would have been if the Merck acquisition (announced in March 2026) had failed to close by May 5, 2026. However, the deal completed as planned, and Te...

Red Flags

🚩Company delisted on May 5, 2026.
🚩No longer trades publicly.
🚩All shareholder equity converted to cash at $53.00/share.

Competitive Moat

PFE

Rating

🛡️ Wide

Trend

➡️ Stable

Intangible Assets/IP (Patents, regulatory approvals, proprietary compounds)Brand Power (Trust, reputation in healthcare)Cost Advantages (Scale in manufacturing and R&D)Switching Costs (Physician familiarity, established treatment protocols)

TERN

Rating

🛡️ None

Trend

➡️ Not Applicable

Investment Thesis

PFE4.0/10

If Pfizer's non-COVID product portfolio (e.g., Vyndaqel, Eliquis, newly launched oncology/rare disease drugs) continues to deliver mid-single-digit operational growth (above +5% YoY) and its late-stage pipeline yields 2-3 significant approvals (>$500M potential) over the next 18-24 months, then it could stabilize revenue around its $60B guidance range and see a modest re-rating to a 12-13x forward...

Full PFE Analysis

TERN0.1/10

The investment thesis for Terns Pharmaceuticals as a high-risk, high-reward 10x growth opportunity is entirely negated. The company was acquired by Merck for $53.00 per share and subsequently delisted on May 5, 2026. All independent growth potential has been capitalized and transferred to Merck. Terns no longer represents a viable investment for public equity investors.

Full TERN Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and Comirnaty contracts offer stability, but these are incremental gains for a company of Pfizer's scale....

Full PFE Analysis

TERN0.1/10

Score Change Explanation: The score has been maintained at an extremely low level (0/100, down from the previous 1/100) to reflect the definitive and irreversible change in Terns Pharmaceuticals' status. On May 5, 2026, Merck completed its acquisition of TERN for $53.00 per share, and the company has since been delisted from Nasdaq. This corporate action entirely eliminates TERN's independent existence as a public company and, consequently, any possibility of it generating 10x growth for public ...

Full TERN Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.